|
|
 |
|
Viewing report
|
|
|
|
Insights into Platform Technology and Early-Stage Pipeline Mergers and Acquisitions
Decision Resources, Inc., March 2009, Pages: 24
The continuing activity in mergers and acquisitions (M&As) involving biotechnology companies reflects the industry’s growth and maturity. Biotech companies are increasingly merging for strategic reasons that include business, clinical, and technological considerations. In addition to seeking marketed and late-stage clinical candidates, Big Pharma is acquiring biotech companies to gain earlystage pipelines and technological innovation that can drive drug discovery.
Get the Answers You Need to Shape Your Strategy
- Big Pharma is continuing the trend of acquiring of biotech companies; overall, life sciences M&As have surged in recent years. What factors are driving pharma-biotech M&As? What strategic interests do these M&As serve?
- Pharmaceutical companies have showed renewed interest in companies with innovative technology platforms capable of yielding novel leads and/or products. Which technology platforms feature in recent, high-value pharma-biotech M&As? Which companies are attracting the interest of Big Pharma for M&A?
- Because so many investigational compounds fail in clinical development—including late-stage compounds in Phase III clinical trials--acquiring a company solely for its pipeline is risky. How can companies mitigate the risks of early pipeline acquisition? Which recent M&A deals include features that mitigate this risk?
- Big Pharma’s preference for partnering with or acquiring either platform technology or product companies has oscillated throughout the history of the biotech industry. What factors determine the value that investors place on platform technologies? Will the pharmaceutical industry’s interest in acquiring platform technologies continue?
Scope
- Life science M&As: pharma-biotech M&A drivers.
- Novel targets and early-stage pipelines: sirtuins, Hsp-90, kinases, risk management.
- Therapeutic platforms: therapeutic antibodies, artificial protein scaffolds, RNAi therapeutics.
- Target and lead discovery: RNAi technology, profiling drug efficacy, lead optimization, chemistries, glycosylation.
- Molecular diagnostics: patient-specific therapy, translational medicine, biomarkers, signature profiling.
- Industry outlook: profitable biotechs, therapeutic antibodies, next-generation antibodies, protein optimization, value of innovative technology platforms.
Technologies, Targets, and Platforms
- Albumin fusion technology
- Antibody fragments
- Antibody humanization
- Antibody identification
- Antibody optimization
- Artificial protein scaffolds
- Biomarkers
- Cell-based assays
- Cocrystallization
- Glycosylation engineering
- Hsp-90
- Kinases
- Lead discovery
- Lead optimization
- Molecular diagnostics
- Nuclear magnetic resonance
- Pegylated cationic-lipid complexes
- Protein therapeutics
- Ribosome display
- RNA display
- RNAi libraries
- RNAi therapeutics
- Signature profiling
- Single-chain antibodies
- Sirtuins
- Structure-based drug design
- Target capture
- Target discovery
- Therapeutic antibodies
- Translational medicine
- X-ray crystallography
Customers who bought this item also bought
Dealmaking and Financing: Mergers and Acquisitions in Key Markets
Global Mobile Phone Platform (Baseband) Industry Report, 2007-2008
Global Mobile Phone Platform (Baseband) Industry Report, 2007-2008
What To Look For If You’re Buying Network Management From An ESM Platform Provider - An Advisory Note
Pharma Antes Up: Investment and Business Trends Driving Biotechnology
Global Health IT Review (January-March, 2008)
Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances
Fueling the Drug Discovery Engine: Biotech Investment and Business Trends
SPECIAL REPORT: Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout?
Inside the Customer Universe: How to Build Unique Customer Insight for Profitable Growth and Market Leadership
Strategies for Building Early-Stage Pharmaceutical Pipelines Through External Sources
Merger & Acquisition Deal Analysis - Reliance Industries And Reliance Petroleum Boards Approve Their Merger
|
|
|
|
